Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects
Author:
Affiliation:
1. Clinical Pharmacology/Quantitative Pharmacology/Translational Medicine EMD Serono (a business of Merck KGaA, Darmstadt, Germany) Billerica MA USA
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1953
Reference81 articles.
1. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
2. European Medicines Agency.Dose–response information to support drug registration E4: ICH Harmonised Tripartite Guidelines (1994).
3. US Food and Drug Administration.Guidance for industry: exposure–response relationships‐study design data analysis and regulatory applications (2003).
4. Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
5. Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients;British Journal of Clinical Pharmacology;2023-12-29
2. Confounded exposure metrics;CPT: Pharmacometrics & Systems Pharmacology;2023-11-20
3. Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature;Clinical and Translational Science;2023-11-14
4. Population Pharmacokinetics and Exposure–Response Analysis for the CTLA‐4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study;Clinical Pharmacology & Therapeutics;2023-10-17
5. Case–control matching‐guided exposure‐efficacy relationship for avelumab in patients with urothelial carcinoma;CPT: Pharmacometrics & Systems Pharmacology;2023-10-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3